Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 26, 2007
-
COMMENTARY Japanese Pharma Companies' Licensing Policy: 1 (1) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
-
ARCHIVE Generics to Be Listed for 6 Major Products with Sales of Over \10 Bil.
March 26, 2007
-
ARCHIVE 152 Generics Approved for the Same Indications as Original Drugs
March 26, 2007
-
ARCHIVE Generics Should Use the Same Excipients as Original Drugs: Dr Kawashima of Santen
March 26, 2007
-
ARCHIVE NEW PRODUCT
March 26, 2007
-
ARCHIVE Kyorin to License at Least 1 Compound Per Year at Late Stage
March 26, 2007
-
ARCHIVE Korosho Proposes 7 Measures to Promote Innovation
March 26, 2007
-
COLUMN Maurer's Healthcare Insight (84)
March 26, 2007
-
ARCHIVE Japan-China Medical Cooperation Initiatives to Symbolize Fraternity: Mr Niwa
March 26, 2007
-
ARCHIVE Results of J-LIT Subanalysis Published: Banyu
March 26, 2007
-
ARCHIVE R&D NEWS IN BRIEF
March 26, 2007
-
COMMENTARY Japanese Pharma Companies' Licensing Policy: 1 (2) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
-
ARCHIVE FPMAJ to Propose NHI Pricing System Reform Plan in August
March 26, 2007
-
COMMENTARY Comentary
March 26, 2007
-
ARCHIVE Required Nos. of Japanese Subjects Are Not Exorbitant: Mr Mori from PMDA
March 26, 2007
-
COMMENTARY Future of the Life Sciences Industries: Strategies for Success in 2015
March 19, 2007
-
ARCHIVE R&D NEWS IN BRIEF
March 19, 2007
-
ARCHIVE Mr Matsumoto Likely to Serve 4th Term as JACDS President
March 19, 2007
-
ARCHIVE Korosho to Issue GL on Ads on Medical Services
March 19, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…